ClinicalTrials.gg
Active, not recruitingNCT06815627Updated Jul 9, 2026

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

A Phase 3 interventional study of NH002 (Perflutren Lipid Microspheres) Injectable Suspension in Cardiac Diseases, sponsored by Trust Bio-sonics, Inc.. Active, not recruiting at 6 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Trust Bio-sonics, Inc. · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Heart Diseases with a site in Taiwan — 4 open to participants now, 7 under way, 3 of them phase 3. Heart Diseases · Taiwan.

Planned enrollment
18th of 22
150 · median 556
Started
2025
with 3 others
Phase 3
8 of 25
2 open now
Registered
23rd of 25
by date
Lead sponsor
2 of 25
Trust Bio-sonics, Inc.

Among the 25 studies in Heart Diseases with a site in Taiwan, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 in phase 3, and was the 23rd registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

4 of the 25 studies in Heart Diseases with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 181 Heart Diseases studies recruiting now, 128 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 32 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Heart Diseases with a site in Taiwan, or all of them as a file.
02

Study summary

This is a Phase 3, prospective, open-label, multicenter study to assess the efficacy of NH002-enhanced echocardiography in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the left ventricular endocardial border delineation compared with unenhanced echocardiography. The study also aims to investigate the safety and tolerability of NH002.

03

Conditions studied

  • Cardiac Diseases

Browse trials for

Keywords

  • Echo
  • Echocardiogram
  • Cardiac ultrasound
  • suboptimal
  • contrast agent
  • enhancing agent
  • LVO
  • LVEBD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. Ability to understand and the willingness to provide written
  3. Having or suspected of having cardiac disease
  4. Undergone a transthoracic echo within 30 days prior to NH002 dose administration, resulting in suboptimal LVEBD, as defined by 2 or more segments of 6 segments of the ventricular border that cannot be visualized reliably in any of the standard apical 4-, 2-, and 3-chamber views during the resting non-contrast ultrasound examination

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if one or more of the following exclusion criteria are applicable:

  1. Any evidence of other severe or unstable cardiopulmonary and/or systemic hemodynamic conditions deemed unsuitable for the study by the investigator(s) prior to NH002 dose administration, including, but not limited to:

    1. ongoing or recent acute coronary syndrome within 6 months.
    2. uncontrolled serious ventricular arrhythmias.
    3. decompensated or inadequately controlled congestive heart failure ( Class IV).
    4. atrial fibrillation or current uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise.
    5. uncontrolled hypertension (i.e., resting systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg or arterial hypotension [defined as systolic blood pressure ≤ 90 mmHg]).
    6. acute aortic dissection.
  2. Known or suspected to one or more of the ingredients of NH002, perflutren, Definity®, or other echocardiographic contrast agents
  3. Known or suspected hypersensitivity to polyethylene glycol, prior reactions to common polyethylene glycol-containing products such as colonoscopy bowel preparations, and certain laxatives (e.g., Miralax)
  4. Received an compound within 30 days before enrolling in the study
  5. Received any contrast agent either intravascularly or orally within 48 hours prior to NH002 dose administration
  6. Pregnant or lactating female. Exclude the possibility of pregnancy:

    1. testing on-site at the institution (serum or urine β-human chorionic gonadotropin) within 24 hours prior to the start of NH002 dose administration, and
    2. history of using an adequate and medically approved method of to avoid pregnancy for at least 1 month prior to NH002 dose administration and willing to continue using the same method for the duration of the study, or
    3. surgical history (e.g., tubal ligation or hysterectomy), or
    4. with a minimum of 1 year without menses.
  7. Serious medical or psychiatric illness/condition likely, in the judgment of the investigator, to interfere with compliance to protocol treatment/research
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    NH002

    Subjects will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination (following intravenous (IV) doses of NH002: 2.5 µl/kg) on the same day.

    Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Left Ventricular Endocardial Border Delineation (LVEBD)

    The first primary efficacy endpoint will be the change from baseline in total LVEBD scores (UEUS vs CEUS) defined using a 16-segment model derived from the standard 17-segment model, as assessed through blinded central reading. The LV endocardium of the standard apical 4-, 2-, and 3-chamber views is divided into 6 segments, with 2 basal, mid-, and apical segments in each view, of which 2 segments are shared in the standard apical 4- and 3-chamber views (i.e., a total of 16 segments in the 3 views). The 17th segment at the apex will not be scored since it does not connect to any part of the LV endocardial border. For each segment, LVEBD is graded as follows: 0 = inadequate border (border not visible); 1 = sufficient (border barely visible); 2 = good (border clearly visible). A total delineation score (0 to 32) is obtained by adding the scores from a total of the 16 segments in the 3 views.

    Time frame: Image data obtained pre-injection and within 10 minutes post-injection

  2. Left Ventricular Opacification (LVO)

    The co-primary endpoint will be the proportion of subjects with adequate LVO defined by an LVO grade of +2 (moderate) or +3 (complete), as assessed through blinded central reading.

    Time frame: Image data obtained pre-injection and within 10 minutes post-injection

Secondary outcomes

  1. The number and percentage of subjects with suboptimal echocardiography converted into optimal echocardiography

    Objective evaluation of the number and percentage of subjects with suboptimal echocardiography (based on the definition of inadequate LVEBD; i.e., at least two segments \[combined chamber view\] with an LVEBD score of 0) converted into optimal echocardiography following administration of study drug will be summarized for each reader.

    Time frame: Image data obtained pre-injection and within 10 minutes post-injection

  2. Standard 12-lead ECG QT interval

    Standard 12-lead ECG QT interval assessed prior to injection and at 10 and 30 minutes after the end of injection; and at 24 hours after the end of injection

    Time frame: From pre-injection to 24 hours post injection

  3. Blood Pressure (BP)

    Changes in BP assessed prior to injection and at 5, 10, and 30 minutes the end of after injection; and at 24 hours after the end of injection

    Time frame: From pre-injection to 24 hours post injection

  4. Heart Rate (HR)

    Changes in HR assessed prior to injection and at 5, 10, and 30 minutes the end of after injection; and at 24 hours after the end of injection

    Time frame: From pre-injection to 24 hours post injection

  5. SpO2

    SpO2 assessed by pulse oximetry prior to injection and at 5, 10, and 30 minutes after the end of injection; and at 24 hours after the end of injection

    Time frame: From pre-injection to 24 hours post injection

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 23 months after the start.

Of 32 phase 3 interventional studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Feb 7, 2025
StartActual
Mar 18, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06815627
Lead sponsor
Trust Bio-sonics, Inc.
Collaborators
CMIC ASIA-PACIFIC, PTE. LTD., TAIWAN BRANCH
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Mar 18, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Wen-Chung Yu
principal investigator · Taipei Veterans General Hospital, Taiwan
Chung-Lieh Hung
principal investigator · Mackay Memorial Hospital
Chih-Hui Chin
principal investigator · Cathay General Hospital
Hsin-Yueh Liang
principal investigator · China Medical University Hospital
Ning-I Yang
principal investigator · Chang Gung Memorial Hospital
Chien-Boon Jong
principal investigator · National Taiwan University Hospital Hsin-Chu Branch

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perflutren

Start the discussion